PTEN缺失合并ERG阴性状态与根治性前列腺切除术后致死性疾病相关
单中心791例临床局限型前列腺癌根治术患者,用经验证的免疫组化检测PTEN/ERG状态,中位随访12.8年。多变量Cox分析显示PTEN缺失与致死性前列腺癌风险升高相关(HR 1.9,95%CI 1.2-3.0,p=0.012),该关联仅见于ERG阴性亚组(HR 2.3,95%CI 1.3-4.1,p=0.005),ERG阳性亚组无统计学意义。
要点
- PTEN缺失与根治术后致死性前列腺癌风险升高相关(HR 1.9)。
- 该风险仅在ERG阴性肿瘤中显著(HR 2.3),ERG阳性者无关联。
- PTEN/ERG状态可用于手术患者的风险分层。
核心结论
- PTEN缺失与根治性前列腺切除术后致死性前列腺癌风险升高相关,且在ERG阴性肿瘤亚组中最显著。
研究设计与样本
- 单中心纳入791例临床局限型前列腺癌根治术患者,用组织芯片行经验证的免疫组化检测PTEN和ERG。
- 采用多变量Cox比例风险模型,校正年龄、种族、病理分级、病理分期和手术切缘状态。
主要发现
- 中位随访12.8年,791例中203例(25%)存在PTEN缺失,776例中330例(43%)为ERG阳性。
- 多变量分析中PTEN缺失与致死性前列腺癌风险升高相关(HR 1.9,95%CI 1.2-3.0,p=0.012),ERG表达无统计学意义(HR 0.6,95%CI 0.4-1.1,p=0.11)。
- PTEN缺失与致死性疾病的关联仅见于ERG阴性肿瘤(HR 2.3,95%CI 1.3-4.1,p=0.005),ERG阳性肿瘤中无关联(HR 1.1,95%CI 0.6-2.1,p=0.81)。
关键数值与推荐
- 致死性前列腺癌定义为转移或前列腺癌特异性死亡。
- PTEN缺失合并ERG阴性者致死性前列腺癌风险升高(HR 2.3,95%CI 1.3-4.1,p=0.005)。
临床怎么用
- 根治性前列腺切除术后可结合PTEN和ERG状态进行风险分层,尤其关注ERG阴性且PTEN缺失的患者。
局限性
- 单中心回顾性设计,样本来自单一机构。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Few groups have investigated the combined effects of PTEN loss and ERG expression on the outcomes of metastasis of or death from prostate cancer in surgically treated patients. We examined the association of PTEN/ERG status with lethal prostate cancer in patients treated with radical prostatectomy. MATERIALS AND METHODS: Included in analysis were 791 patients with clinically localized prostate cancer treated with radical prostatectomy at a single institution. Genetically validated immunohistochemistry assays for PTEN and ERG were performed on tissue microarrays. Multivariable Cox proportional hazard models were used to assess the association of PTEN/ERG status with lethal prostate cancer (defined as metastasis or prostate cancer specific death), adjusting for patient age, race, pathological grade and stage, and surgical margin status. RESULTS: Median followup in the cohort was 12.8 years. Of 791 cases 203 (25%) demonstrated PTEN loss and 330 of 776 (43%) were ERG positive. On multivariable analysis PTEN loss (HR 1.9, 95% CI 1.2-3.0, p=0.012) but not ERG expression (HR 0.6, 95% CI 0.4-1.1, p=0.11) was associated with an increased risk of lethal prostate cancer. The association of PTEN loss with lethal disease only remained among men with ERG negative tumors (HR 2.3, 95% CI 1.3-4.1, p=0.005) and not ERG positive tumors (HR 1.1, 95% CI 0.6-2.1, p=0.81). CONCLUSIONS: PTEN loss is associated with an increased risk of lethal prostate cancer after radical prostatectomy and this risk is most pronounced in the subgroup of patients with ERG negative tumors. This work corroborates the use of PTEN and ERG status for risk stratification in surgically treated patients.
引用
- Haney NM, Faisal FA, Lu J, et al. PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy. J Urol. 2019. PMID: 31502941. doi:10.1097/JU.0000000000000533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。